drugset / Trial / NCT03595488

Dupilumab for Aspirin-exacerbated Respiratory Disease

NCT03595488

Phase 2 Completed 11 enrolled Rochester General Hospital
NaSingle-groupOpen-labelTreatment

Summary

Subjects with physician-diagnosed aspirin-exacerbated respiratory disease (AERD) who remain unacceptably symptomatic with a SNOT 22 score \> 18 despite routine medical therapy will be enrolled in this single center, single-blinded study assessing the efficacy of dupilumab in AERD.

Timeline

Start
2018-09-05
Primary completion
2019-12-11
Completion
2019-12-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dupilumab Monoclonal antibody 300 mg Subcutaneous